Latest News About Ramipril Recall

Here are the latest publicly reported updates on ramipril recalls as of now:

• UK MHRA: Precautionary recalls and batch alerts in 2026

  • Several batches from Crescent Pharma Limited Ramipril have prompted precautionary recalls and stop-supply notices. Patients are advised to check batch numbers and return affected stock to pharmacies or suppliers, with guidance to contact a GP or pharmacist if in doubt. This includes specific batch designations like GR155023 and related packaging warnings. These actions are part of ongoing manufacturing-safety safeguards.[7][8]

• UK public health updates and risk communications

  • The MHRA and UK government communications emphasize checking packaging, stopping use of impacted batches, returning stock, and reporting any adverse effects via the Yellow Card scheme. Healthcare professionals have been instructed to quarantine affected stock and assist patients during transitions to safe alternatives.[8][7]

• US recall context from late 2024

  • The FDA did issue recalls of Ramipril produced by Lupin Pharmaceuticals after an active pharmaceutical ingredient was sourced from an unapproved vendor, leading to removal of tens of thousands of bottles. Patients were advised to consult their pharmacist or prescriber if their Ramipril product matched the recalled lots. This recall highlighted potential quality-control concerns in supply chains for Ramipril in the US.[1]

• Ongoing international and recall-related warnings

  • Reports from different regions in 2026 indicate recalls or batch-level alerts for Ramipril capsules due to manufacturing errors or mislabeling, with specific batch numbers being referenced in official notices. Patients should verify their batch numbers and discontinue use if they match recalled lots, seeking a clinician’s guidance for alternatives.[3][5][9]

What you should do if you or someone you know takes Ramipril right now

• Check the packaging for batch numbers and lot codes mentioned in official recall notices (for example, GR155023 or other batch identifiers cited by your country’s health authority).
• Do not take capsules from any batch that is listed in a recall notice; return them to your pharmacy or follow local guidance for disposal.
• Contact your pharmacist or prescriber promptly to discuss safer alternatives or adjustments to your therapy, especially if you’re currently on Ramipril for hypertension or heart-related conditions.
• Monitor for any unusual symptoms such as dizziness, fainting, or symptoms of low blood pressure and report them to a clinician or the appropriate reporting system in your country (for example, a Yellow Card or equivalent).

If you’d like, I can:

• Look up the exact batch numbers currently recalled in your country and provide a concise, country-specific checklist.
• Help you assemble a quick script to call your pharmacist or doctor to confirm whether your Ramipril is affected and discuss alternatives.
• Create a simple one-page printable note with the recall steps and the contact numbers you’ll need.

Would you like me to narrow this to your location (Montréal, Quebec) and pull Canada-specific recall details, or focus on the UK/EU updates? I can also summarize the most recent batch numbers relevant to you in a compact list.